Search results
Remdesivir has no significant effect on patients with COVID-19 who are already being ventilated. Among other hospitalised patients, it has a small effect against death or progression to ventilation (or both).
W uwzględnionych badaniach porównano stosowanie remdesiwiru wraz ze standardową opieką zdrowotną lub standardową opieką zdrowotną (z placebo lub bez niego) u hospitalizowanych chorych na COVID-19. Pacjenci hospitalizowani z umiarkowanym lub ciężkim przebiegiem COVID-19.
22 gru 2021 · A 3-day course of remdesivir had an acceptable safety profile and prevented disease progression resulting in hospitalization among high-risk patients with Covid-19.
21 lut 2023 · This individual patient data meta-analysis showed that remdesivir reduced mortality in patients hospitalised with COVID-19 who required no or conventional oxygen support, but was underpowered to evaluate patients who were ventilated when receiving remdesivir.
21 maj 2022 · Therefore, treatment or combination treatments considered most appropriate can vary among patients. 3,4 However, most randomised studies assessing response to specific treatments have, to date, included all patients with COVID-19, irrespective of phenotype assessment.
Forty-seven cases were treated with a 3-day course of remdesivir (200 mg on day 1 and 100 mg on days 2 and 3) within a median time of 1.4 day from testing positive, and were compared to a matched case-control cohort of 43 untreated patients; matching was based on age, sex, vaccination status, previous symptomatic infections by SARS-CoV-2 ...
27 maj 2020 · Patients were randomly assigned in a 1:1 ratio to receive intravenous remdesivir for either 5 days or 10 days. All patients received 200 mg of remdesivir on day 1 and 100 mg once daily on ...
